Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Bumrungrad Hospital Q1 2026: earnings and revenue expectations exceeded, stock falls premarket
Bumrungrad Hospital reported Q1 2026 EPS of $2.06 versus a $2.04 estimate and revenue of $6.2 billion (expectation $5.98 billion). EBITDA rose 5% and revenue from non-Thai patients increased 4.2%, while revenue from Thailand fell 3.6%. The share price fell 2.86% premarket to $170, pressured by declining domestic sales and longer receivable days (71.7 days). Management does not plan further price increases and is focusing on international expansion and growing outpatient and robot-assisted services. » More on de.investing.com
Bumrungrad Hospital beats Q1 forecasts, stock falls nonetheless
Bumrungrad Hospital reported Q1 2026 earnings per share of $2.06 (expectation $2.04) and revenue of $6.2 billion (forecast $5.98 billion). The EBITDA margin rose to a record high of 39.3%, driven by growth in non‑Thai patients, notably from the Middle East. Despite the stronger metrics, the share price fell 2.86% in premarket trading. The company plans capacity expansions (Phuket project, » More on de.investing.com
Bumrungrad Hospital PCL posts record EBITDA margin despite revenue decline
Bumrungrad Hospital PCL reported Q2 2025 revenue down 3.6% to THB 6,104 million, EBITDA of THB 2,537 million (-1.6%), and a record EBITDA margin of 41.6%; net profit fell 3.8% to THB 1,858 million with a near-stable net margin of 30.4%. The share of international patients dropped to 64%, international revenue declined 6.6%, while Middle East revenue rose sequentially versus Q1 (UAE +46%, Saudi Arabia +54%, Oman +28%). The company has a strong net cash position, is investing in robotics and specialty centers, and paid THB 2 per share in the first half with a 44% payout ratio. » More on de.investing.com
Bumrungrad Hospital achieves record EBITDA margin despite revenue decline in Q2 2025
Bumrungrad Hospital reported a 3.6% decrease in revenue for the second quarter of 2025, but achieved a record EBITDA margin of 41.6% thanks to effective cost control. The net profit margin remained stable, and the company increased its dividend payout while advancing strategic investments such as the planned cancer center and the expansion of robotic surgery. The Middle East market showed a strong recovery, while challenges persisted in other regions such as China. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 163.77m | 3.95% |
| Gross profit | 85.23m | 3.12% |
| Net profit | 49.65m | 2.20% |
| EBITDA | 67.09m | 0.94% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.33bn |
Number of shares | 794.97m |
52-week high/low | €5.45 - €4.41 |
Dividend yield | 6.65% |
Dividends TTM | €0.34 |
Beta | 0.18 |
P/E ratio | 20.08 |
PEG ratio | 9.90 |
P/B ratio | 5.64 |
P/S ratio | 5.99 |
Company profile
Bumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. The company offers diagnostic, therapeutic, and intensive care facilities in a medical center. Its outpatient clinics/centers include allergy, arrhythmia, behavioral health, breastfeeding, breast care, children, dental, diabetes, diagnostic, dialysis, digestive disease, emergency, eye, fertility and IVF, health screening, hearing and balance, heart valve, cancer, hyperbaric oxygen therapy, hypertension, joint replacement, liver, memory, men, nephrology, neuroscience, new life healthy aging, orthopedic, Parkinson's disease and movement disorders, perinatal, physical therapy and rehabilitation, plastic surgery, pulmonary, refractive surgery, robotic scoliosis and surgery, skin, sleep lab, spine, sports medicine and lifestyle, surgical, travel medicine, urology, vitalife, and women's, as well as ear, nose, and throat centers. In addition, the company is involved in the real estate assets holding activities; provision of clinical research services; distribution of pharmaceutical and medical goods in specialized stores; operation of personnel development and training center for healthcare services; and patient referral service business. It operates 580 beds and approximately 56 clinics/centers. The company was founded in 1980 and is headquartered in Bangkok, Thailand.
| Name | Bumrungrad Hospital PCL |
| CEO | Artirat Charukitpipat |
| Headquarters | Bangkok,
bm Thailand |
| Website | |
| IPO | 31/12/2007 |
| Employees | 4,506 |
Ticker symbols
| Exchange | Symbol |
|---|---|
XETRA | BZ7A.F |
Pnk | BUHPF |
München | BZ7A.MU |